Ignota Labs, the AI-driven drug turnaround company, has announced the close of a $6.9 million (£5.5 million) seed funding round, co-led by Montage Ventures and AIX Ventures with participation from Modi Ventures, Blue Wire Capital, and Gaingels. The funding will be used to expand the pipeline by acquiring additional distressed assets and for advancement into early-stage clinical trials of their first asset, a PDE9A inhibitor.
Source link
